Bacillus calmette-guerin substrain danish 1331 live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bacillus calmette-guerin substrain danish 1331 live antigen
DrugBank Accession Number
DB12386
Background

BCG SSI has been used in trials studying Tuberculosis.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • BCG (SSI strain)
  • BCG SSI

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Altretamine.
AmantadineThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Amantadine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
4CGF0IDN3W
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911329

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingPreventionBCG Vaccination Reaction / Tuberculosis (TB)1
3RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / Heterologous Immunity / Immunosenescence / Morbidity / Non-specific Effects of Vaccines / Vaccine Preventable Disease1
2CompletedPreventionTuberculosis (TB)1
1CompletedPreventionTuberculosis (TB)1
Not AvailableCompletedNot AvailableTuberculosis (TB)2
Not AvailableCompletedPreventionTuberculosis (TB)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on October 20, 2016 22:10 / Updated on June 12, 2020 16:53